July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
c-Jun mediated microRNA-302d-3p induces RPE dedifferentiation and CNV formation by targeting p21Waf1/Cip1
Author Affiliations & Notes
  • Xue Chen
    Ophthalmology, Nanjing Medical University, Nanjing, China
  • chao jiang
    Ophthalmology, Nanjing Medical University, Nanjing, China
  • Chen Zhao
    Department of Ophthalmology and Vision Science, Eye & ENT Hospital, Nanjing, Jiangsu, China
  • Footnotes
    Commercial Relationships   Xue Chen, None; chao jiang, None; Chen Zhao, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 359. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xue Chen, chao jiang, Chen Zhao; c-Jun mediated microRNA-302d-3p induces RPE dedifferentiation and CNV formation by targeting p21Waf1/Cip1. Invest. Ophthalmol. Vis. Sci. 2018;59(9):359.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dedifferentiation of retinal pigment epithelium (RPE) and choroidal neovascularization (CNV) contributes to the pathogenesis of age-related macular degeneration (AMD). MicroRNAs (miRNAs) play crucial roles in AMD onset and progression. We aim to illustrate the effects and mechanisms of miRNAs on RPE dedifferentiation and CNV formation.

Methods : Microarray was applied to identify RPE differentiation relevant miRNAs. Bioinformatics analysis and luciferase reporter assay were performed to identify the up-stream transcript factor (TF) and down-stream target of miR-302d-3p. Q-PCR, western blot, immunofluorescence, flow cytometric analysis, analyses of proliferation and migration, and tube formation assay were conducted to reveal the role of miR-302d-3p in regulating RPE function and CNV formation.

Results : Microarray identified miR-302d-3p as the most down-regulated miRNA signature along with RPE differentiation. In vitro study further supported that miR-302d-3p induces RPE dedifferentiation and apoptosis, promotes its migration, proliferation and cell-cycle progression, and interrupted its phagocytosis. c-Jun was identified as a upstream TF for MIR302D, which potentially modulated RPE function by regulating miR-302d-3p expression. P21Waf1/Cip1, a cyclin-dependent kinase inhibitor encoded by the CDKN1A gene, was identified as a down-stream target of miR-302d-3p. P21Waf1/Cip1 promoted RPE differentiation, and inhibited its proliferation, migration and cell-cycle progression. MiR-302d-3p suppressed RPE differentiation through directly targeting p21Waf1/Cip1. In addition, the miR-302d-3p/ p21Waf1/Cip1 axis was also involved in regulating tube formation of endothelial cells, suggesting its role in CNV generation.

Conclusions : Our study implies that miR-302d-3p, regulated by c-Jun, contributes to the pathogenesis of both atrophic and exudative AMD. MiR-302d-3p promotes RPE dedifferentiation, migration, proliferation, cell-cycle progression and apoptosis, inhibits RPE phagocytosis, and induces CNV by targeting p21Waf1/Cip1. Pharmacological miR-302d-3p inhibitors are prospective therapeutic options for prevention and treatment of AMD.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

c-Jun mediated miR-302d-3p inhibits RPE differentiation and phagocytosis, and promotes RPE apoptosis, proliferation, migration and cell-cycle progression.

c-Jun mediated miR-302d-3p inhibits RPE differentiation and phagocytosis, and promotes RPE apoptosis, proliferation, migration and cell-cycle progression.

 

MiR-302d-3p mediates RPE function and HUVEC tube formation by directly targeting p21Waf1/Cip1.

MiR-302d-3p mediates RPE function and HUVEC tube formation by directly targeting p21Waf1/Cip1.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×